Search All UT System Experts

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. AtkinsDavid F. McDermott

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences